-
-
-
-
-
-
-
Regeneron (REGN) Tops Q3 EPS by 219c
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Lowered to $979 at Bernstein Amid 'Eylea Headwinds'
-
-
-
-
-
-
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
-
-
-
-
-
-
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit- Hagens Berman
-
-
-
-
-
-
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
-
-
-
-
-
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

